新聞資訊

按年份搜索
2016年08月15日

Serving returns: How Ally Bridge expects to build on top of WuXi arbitrage play

China’s Ally Bridge Group hit the investment world’s radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with the listing of WuXi’s biologics unit in Hong Kong this year, the question is what will be its next moves to generate outsized returns for its investors.

BioCentury 8.15.16

返回資訊